HighTower Advisors
PALI icon

HighTower Advisors’s Palisade Bio PALI Stock Holding History

HighTower Advisors’s Portfolio PALI Stock Details PALI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-22
Closed -$44K – 3421
2021
Q3 		$44K Hold
22
– – ﹤0.01% 2948
2021
Q2 		$68K Hold
22
– – ﹤0.01% 2858
2021
Q1 		$170K Hold
22
– – ﹤0.01% 2653
2020
Q4 		$88K Sell
22
-11
-33% -$33K ﹤0.01% 2363
2020
Q3 		$87K Buy
+33
New +$105K ﹤0.01% 2250
2019
Q4 		– Sell
-10
Closed -$75K – 2495
2019
Q3 		$75K Buy
+10
New +$139K ﹤0.01% 2195
2016
Q4 		– Hold
0
– -$29K – 2006
2016
Q3 		– Hold
0
– – – 1809
2016
Q2 		– Hold
0
– – – 1669

Other funds holding PALI

ACM
Altium Capital Management New York $42M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SWIG
Strategic Wealth Investment Group Louisville, Kentucky $788M AUM 14.6% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.3B AUM 22.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

HighTower Advisors's PALI Position: Q4 2021 in Review

HighTower Advisors sold out of Palisade Bio (PALI) in Q4 2021, closing a stake of 22 shares — an estimated $44K sold.

HighTower Advisors first reported a position in PALI in Q3 2019 and held it in 6 quarters. The position peaked at $170K in Q1 2021. 21 funds tracked by Wall St. Rank hold PALI as of Q4 2021.

  • HighTower Advisors reported no remaining Palisade Bio position as of Q4 2021 after selling out during the quarter.
  • HighTower Advisors sold 22 Palisade Bio shares in Q4 2021, an estimated $44K.
  • HighTower Advisors first reported a position in Palisade Bio in Q3 2019 and held it in 6 quarters.
  • HighTower Advisors's Palisade Bio position peaked at $170K in Q1 2021.
  • 21 funds tracked by Wall St. Rank held Palisade Bio as of Q4 2021.

Based on HighTower Advisors's 13F filing for Q4 2021, filed 10 Feb 2022.